Skip to main content
SpringerLink
Log in

Efficacy of Nimotuzumab Combined with Docetaxel–Cisplatin–Fluorouracil Regimen in Treatment of Advanced Oral Carcinoma

  • Translational Biomedical Research
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

The present study aimed to evaluate efficacy and adverse effects of Nimotuzumab combined with docetaxel–cisplatin–fluorouracil regimen in the treatment of advanced oral carcinoma. Nine patients with advanced oral carcinoma were treated with Nimotuzumab combined with docetaxel–cisplatin–fluorouracil regimen (test group). The treatment was given as follows: Nimotuzumab 200 mg, given as intravenous infusion once a week for 6 weeks; docetaxel and cisplatin, 75 mg/m2 each, on day 1 only; 5-fluorouracil, 750 mg/m2 infused continually for 8 h, used from day 1 to 5; the total cycle was for 21 days. Another eight patients comprised control group (docetaxel–cisplatin–fluorouracil regimen alone). Study patients from both groups were evaluated for objective response. The response rate was significantly (p = 0.044) higher in test group (88.9 vs. 37.5 % in control group). The disease control rate also tended to be higher in test group (100 vs. 62.5 % in control group; p = 0.083). The major adverse effects were bone marrow suppression, nausea, vomiting, and alopecia. The incidence of adverse effects was similar between both study groups. In conclusion, Nimotuzumab combined with docetaxel–cisplatin–fluorouracil regimen is effective and safe in the treatment of advanced oral carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liu, Y., & Zhang, Z. (2010). Epidemiology of oral and oropharyngeal cancer. Foreign Medical Sciences (Section Medgeography), 31, 266–269. in Chinese.

    Google Scholar 

  2. Dutta, P. R., & Maity, A. (2007). Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Letters, 254, 165–177.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Argyriou, A. A., & Kalofonos, H. P. (2009). Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Molecular Medicine, 15, 183–191.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Crombet-Ramos, T., Rak, J., Perez, R., & Viloria-Petit, A. (2002). Antiproliferative, antiangiogenic and proapoptotic activity of H-R3: a humanized anti-EGFR antibody. International Journal of Cancer, 101, 567–575.

    Article  CAS  Google Scholar 

  5. Crombet, T., Torres, L., Neninger, E., Catala, M., Solano, M. E., Perera, A., et al. (2003). Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. Journal of Immunotherapy, 26, 139–148.

    Article  CAS  PubMed  Google Scholar 

  6. Crombet, T., Osorio, M., Cruz, T., Roca, C., del, C. R., Mon, R., et al. (2004). Use of the humanized anti-epidermal growth factor receptor monoclonal antibody H-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. Journal of Clinical Oncology, 22, 1646–1654.

    Article  PubMed  Google Scholar 

  7. Allan, D. G. (2005). Nimotuzumab: Evidence of clinical benefit without rash. Oncologist., 2005(10), 760–761.

    Article  Google Scholar 

  8. Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G (2007) Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol. 2007. 25 (18S), 2006 (abstract).

  9. Pendharkar, D., Gupta, S., Pal, M. K., Hakim, S., & Rashid, T. (2007). Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal antibody H-R3 (Nimotuzumab) with chemotherapy––a study of toxicity profile and tolerance. Journal of Clinical Oncology, 25(18S), 14151.

    Google Scholar 

  10. Sobin, L. H., & Wittekind, C. (2002). TNM classification of malignant tumours (pp. 1–264). New York: Wiley-Liss.

    Google Scholar 

  11. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer, 45, 228–247.

    Article  CAS  PubMed  Google Scholar 

  12. National Cancer Institute––Cancer Therapy Evaluation Program (2003) Common terminology criteria for adverse events v3.0 [S/OL]. http://ctepcancergov/protocolDevelopment/electronic_applications/docs/ctcaev3pdf. 2003.

  13. Vernham, G. A., & Crowther, J. A. (1994). Head and neck carcinoma––stage at presentation. Clinical Otolaryngology & Allied Sciences, 19, 120–124.

    Article  CAS  Google Scholar 

  14. Kurtin, S. E. (2009). Systemic therapies for squamous cell carcinoma of the head and neck. Seminars in Oncology Nursing, 2009(25), 183–192.

    Article  Google Scholar 

  15. Herbst, R. S., Arquette, M., Shin, D. M., Dicke, K., Vokes, E. E., Azarnia, N., et al. (2005). Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 23, 5578–5587.

    Article  CAS  PubMed  Google Scholar 

  16. Vermorken, J., Bourhis, J., Trigo, J., Kies, M., Leon, X., Mueser, M., et al. (2005). Cetuximab (Erbitux®) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (Scchn) refractory to first-line platinum-based therapies. Journal of Clinical Oncology, 23(16S), 5505. abstract.

    Google Scholar 

Download references

Acknowledgments

This research was supported by Xuzhou Science and Technology Program (No. XZZD1017).

Author information

Authors and Affiliations

  1. Department of Stomatology, Xuzhou Central Hospital, Affiliated Xuzhou Hospital, College of Medicine, Southeast University, Xuzhou, 221000, China

    Jian Meng, Qian-ping Gu, Qing-fei Meng, Jie Zhang, Zhi-ping Li, Ya-meng Si & Qian-wei Zhuang

  2. Department of Oral and Maxillofacial Surgery, The Ninth People’s Hospital, College of Medicine, Shanghai Jiaotong University, Shanghai, 200011, China

    Wei Guo

Authors
  1. Jian Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qian-ping Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qing-fei Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jie Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhi-ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ya-meng Si
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qian-wei Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jian Meng or Wei Guo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meng, J., Gu, Qp., Meng, Qf. et al. Efficacy of Nimotuzumab Combined with Docetaxel–Cisplatin–Fluorouracil Regimen in Treatment of Advanced Oral Carcinoma. Cell Biochem Biophys 68, 181–184 (2014). https://doi.org/10.1007/s12013-013-9686-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-013-9686-5

Keywords

Search

Navigation